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Abstract: The effect of a-amylase degradation on the release
of gentamicin from starch-conjugated chitosan microparticles
was investigated up to 60 days. Scanning electron micro-
scopic observations showed an increase in the porosity and
surface roughness of the microparticles as well as reduced
diameters. This was confirmed by 67% weight loss of the
microparticles in the presence of a-amylase. Over time, a
highly porous matrix was obtained leading to increased per-
meability and increased water uptake with possible diffusion
of gentamicin. Indeed, a faster release of gentamicin was
observed with a-amylase. Starch-conjugated chitosan par-
ticles are non-toxic and highly biocompatible for an osteo-
blast (SaOs-2) and fibroblast (L929) cell line as well as
adipose-derived stem cells. When differently produced
starch-conjugated chitosan particles were tested, their cyto-
toxic effect on SaOs-2 cells was found to be dependent on
the crosslinking agent and on the amount of starch used. VC
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INTRODUCTION
Biomaterials with the ability to perform certain medical
functions and subsequently degrade are of great importance.
Their degradation should occur under a controlled mecha-
nism and into easily metabolized products.1,2 Among the
well-known advantages of using biodegradable materials are
the elimination of the long-term presence of foreign materi-
als and the consequent need for a second surgery for
implant removal.1
Several deﬁnitions for biodegradability have been pro-
posed.1,3,4 In the context of biomedical applications, biode-
gradation may be deﬁned as the “gradual breakdown of a
material mediated by a speciﬁc biological activity.”4 When in
contact with tissues, biomaterials start to degrade as a
result of their interaction with biological environments.
Their stability will deﬁne their application in clinics. In drug
delivery applications, biodegradability of the carrier system
affects and ﬁnally controls the release kinetics of the encap-
sulated drugs.5 Thus, the polymeric carriers should degrade
under physiological conditions allowing for the gradual
release of the entrapped drug as well as facilitate repeating
dosages to ensure successful treatments.6,7 At this point, a
major concern related to biodegradable polymers is the pos-
sible toxicity of the leachable molecules and degradation
products derived from the material processing and degrada-
tion.8 Thus, the nature of the materials to be selected as
drug delivery carriers is also a rather important factor to
consider. Polysaccharides are very attractive in this respect
as the degradation process results in nontoxic end products
such as glucose, maltose, and oligosaccharides. These end
products may even be incorporated in the normal metabolic
pathways of the human body.1,9
Chitosan and starch have been extensively employed as
a carrier in drug delivery systems.9–13 Both natural poly-
mers are biocompatible and biodegradable.9 In particular,
starch is a cheap, abundant and edible polysaccharide with
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interesting biodegradable properties.1 Our group has dedi-
cated more than a decade to the research of this poly-
mer.11,14–17 Thus, based on our ﬁndings, we hypothesize
that starch—when blended with chitosan—could improve
the processing characteristics as well as the degradation
and biocompatibility of the chitosan formulation alone.
We previously developed starch-chitosan (ST-CHT)
microparticles formulation loaded with gentamicin sulfate
(GTM) and demonstrated the capacity of the system to pro-
vide a long-term sustained release of biologically active
GTM.11 Our intention was to develop a suitable system to
treat bone infections like osteomyelitis. GTM is an antibiotic
characterized by a wide antibacterial spectrum.18 It is
known to be very efﬁcient in treatments of complicated
infections caused by gram-positive bacteria such as Staphy-
lococcus aureus.18 This bacterium is commonly the cause of
osteomyelitis. Thus, GTM has been the antibiotic of choice
to deal with this type of infection for decades.19 Therefore,
we choose GTM to be incorporated in our system.
Here, we investigated the biodegradability and biocom-
patibility of the GTM-loaded microparticles. Particular inter-
est was centered on enzymatic degradation by a-amylase.
This enzyme is present in many tissues in the human body
including blood1 and saliva.20 In addition, it has a speciﬁc
action in cleaving the a (1–4) glycosidic bond of starch mol-
ecules. Thus, it is expected that a-amylase participates in
the degradation of starch-based biomaterials when placed
in contact with human ﬂuids, tissues and organs. Moreover,
the effect of a-amylase degradation on the release kinetics
of entrapped GTM from the ST-CHT microparticles was also
studied. The extent of degradation was evaluated by meas-
uring the weight loss and the presence of reducing sugars
in the degradation medium. Changes in the chemical struc-
ture as well as in their morphological features were also
analyzed. The biocompatibility of the developed micropar-
ticles was assessed by the use of an osteoblast and a ﬁbro-
blast cell line as well as human primary stem cells. The
effect of material processing conditions such as crosslinking
agent, particle size, particle concentration, and amount of
starch were thoroughly evaluated by using an osteoblast
cell line.
MATERIALS AND METHODS
Materials
The materials studied in this work were chitosan (the vis-
cosity average molecular weight was found to be 385 kDa
and the deacetylation degree 81.25%)11 from Sigma-Aldrich
(USA) and soluble potato starch supplied by ATO (The Neth-
erlands). Both materials were used as received. a-amylase
(EC 3.2.1.1) from Aspergillus Oryzae, 215 U/mg protein, was
obtained from Sigma-Aldrich. Other chemicals were analyti-
cal grade, from Sigma-Aldrich and were used as received.
The human osteoblast cell line (SaOs-2) and the mouse
ﬁbroblast cell line (L929) were purchased from the Euro-
pean Collection of Cell Cultures (ECACC, UK). The human
adipose-derived stem cells were kindly provided by Profes-
sor Martijn van Griensven, MD, PhD (Ludwig Boltzmann
Institute for Experimental and Clinical Traumatology,
Vienna, Austria).
Preparation of starch-conjugated chitosan
microparticles loaded with gentamicin
ST-CHT conjugate was prepared by an initial reductive alkyl-
ation crosslinking method.21 Brieﬂy, starch was oxidized to
produce a polyaldehyde that reacts with the amino group of
chitosan in the presence of a reducing agent. The produc-
tion of the ST-CHT microparticles was then carried out using
a water in oil emulsion technique, as described previously.11
In brief, equal volumes of chitosan (1.5%, w/v) and oxi-
dized starch (2%, w/v) solutions were mixed, and the pH
adjusted to 5.5 by using 0.5 M NaOH. The polymeric solu-
tion was added dropwise into a glass reactor containing
mineral oil with 1% of Tween 80 and emulsiﬁed with a top
stirrer at 600 rpm for 30 min. After emulsion formation,
30 mL of cold acetone was added slowly. The microparticles
were then removed from the reaction medium by ﬁltration
and washed with distilled water/acetone mixture (1:1 v/v).
After alkaline (sodium carbonate buffer solution, 0.5M) and
reduction (sodium borohydride solution, 0.05%) treatments,
the microparticles were washed with distilled water and
allowed to dry at room temperature.
For the particles to be loaded with GTM, 15 mg of GTM
per mL polymer solution was directly added to the poly-
meric solution before the particles formation. Subsequently,
the microparticles were formed following the protocol
described above.
For sterilization of the microparticles, ethylene oxide
(EtO) was used. To perform this, two consecutive EtO cycles
(of 25 hs each) were applied in an industrial autoclave at
45C, in an atmosphere with 88% CO2, 12% EtO, and 50%
humidity. These sterilization conditions have been previ-
ously optimized for starch and starch blended materials
with satisfactory results.22
Enzymatic degradation study: In vitro release of
gentamicin in an enzymatic environment
Pre-weighed samples (unloaded and GTM-loaded ST-CHT
microparticles listed in Table I) were incubated in a 1:10
ratio in 0.01M phosphate buffered saline solution (PBS,
pH5 7.4) containing a-amylase 150.5 U/L, at 37C and
under constant shaking (50 rpm) up to 8 weeks. The con-
centration of a-amylase used in the degradation solution is
in the range of the physiological concentration of this
enzyme found in human blood.23 The buffered enzyme solu-
tion was changed weekly to maintain the desired level of
enzyme activity throughout the experiment. For the preser-
vation of the degradation solution, sodium azide (0.02%)
was added to the buffered enzyme solution (stored at 4C
for further use). As a control, the samples were incubated
in the presence of PBS only. At the end of each degradation
time (1, 2, 3, 7, 14, 30, and 60 days), the supernatants were
removed and stored at 280C for further analysis. The
excess of solution was carefully removed with ﬁlter paper
and the samples were weighed using an analytical balance
(60.01 mg accuracy) for the determination of water
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uptake.8 Subsequently, the samples were thoroughly washed
with distilled water and allowed to dry at room tempera-
ture until presenting constant weight. The ﬁnal weight of
the samples was used for the calculation of the weight loss
in relation to the initial weight.8 The supernatants from the
degradation solutions were used to quantify the amount of
released GTM and to determine the concentration of reduc-
ing sugars released into the solution as a product of the
degradation process.
The quantiﬁcation of the released GTM was performed
by an indirect spectrophotometric method using o-
phtaldialdehyde as derivatizing agent.11 Further details on
this method can be found elsewhere.11,24 For the spectro-
photometric determination, equal volumes of GTM-
containing solutions, o-Phtaldialdehyde reagent and isopro-
panol were mixed. After 30 min of incubation at room tem-
perature, the absorbance was measured at 332 nm. The
GTM amounts were calculated according to a standard
curve. The samples were tested in triplicates in three inde-
pendent assays.
The amount of reducing sugars in the supernatants was
estimated by the dinitrosalicylic acid (DNS) method.25 A cal-
ibration curve was prepared using glucose solutions of
known concentrations. Brieﬂy, standard solutions and sam-
ples were mixed with the DNS reagent (mixture of DNS and
Rochelle salt) under the appropriate conditions and allowed
to react at 100C for 5 min. Finally, the absorbance was
determined using a microplate reader at 540 nm (EL 312e
Biokinetics, BioTek Instruments). The amount of reducing
sugars was reported as the average concentration of three
replicate determinations.
Chemical and physical characterization
Morphological evaluation: Scanning electron microscopy
(SEM). SEM was used to assess the changes on the micro-
particles’ morphology as result of the degradation process.
Following a standard procedure for sample preparation, the
microparticles were mounted onto metal stubs by using a
carbon tape and gold sputter-coated (Sputter Coater SC502,
Fison Instruments, UK). Samples were analysed by SEM
(Leica Cambridge S-360 model, UK) after the different
points in time of degradation studied.
Chemical changes: FTIR. To assess possible changes in the
chemical composition of the microparticles as result of the
enzymatic degradation, the samples were analyzed by FTIR
spectroscopy in a transmission mode (IRPrestige-21 FTIR-
8400S, Shimadzu, Japan) before and after the degradation
process. For the preparation of the samples for FTIR analy-
sis, 1 mg of sample was mixed with 40 mg of spectroscopic
KBr, and then processed into a disc using a manual press
(161–1100 hand press, PIKE Technologies, USA). Transmis-
sion spectra were recorded using at least 32 scans with
4 cm21 resolution and in the spectral range 4000–
600 cm21.
Nuclear magnetic resonance spectroscopy (1H-
NMR). Proton nuclear magnetic resonance (1H-NMR) spec-
tra were obtained (Varian Unit Plus 300 MHz spectrometer)
under the following experimental parameters: 256 scans,
5200 Hz ﬁlter width, 90 pulse corresponding to a pulse
width of 11 ls and 4 s relaxation delay. The experiments
were run at 60C. For the sample preparation, 10 mg of
each sample were dissolved into a mixture of deuterated
solvents, 0.98 mL of deuterium oxide (D2O) and 0.02 mL of
deuterium chloride until complete dissolution and trans-
ferred into a NMR tube (u5 0.3 mm).
Evaluation of cytotoxicity
The biocompatibility of the ST-CHT microparticles was
assessed by performing a standard MTS (3-(4,5-dimethylth-
iazol-2-yl)-5-(3-carboxymethoxyphenyl)-2–(4-sulfophenyl)-
2H-tetrazolium) assay. A human osteoblast cell line (SaOs-
2), a mouse ﬁbroblast cell line (L929) and human adipose-
derived mesenchymal stem cells (AMSCs) were used for this
purpose. The microparticles were placed in direct contact
with cells to evaluate their effect on cell viability. Thus,
SaOs-2, L929 and AMSCs were cultured in 12-well tissue
culture plates at a density of 1 3 105 cells/mL having
1.5 mL/well, using Dulbecco’s modiﬁed Eagle’s medium
(DMEM, Sigma-Aldrich) supplemented with 10% of heat-
inactivated fetal bovine serum (FBS, Biochrom AG, Germany)
and 1% of antibiotic/antimycotic solution (Sigma-Aldrich).
Cells were incubated for 24 h at 37C in a humidiﬁed
atmosphere containing 5% of CO2. At that point in time, the
culture medium was replaced by a suspension of the ST-
CHT microparticles (previously sterilized by EtO) in DMEM
complete medium (1 mg/mL). After 72 h incubation time,
the particles were removed by aspiration to perform the
cytotoxicity assay. The MTS test was performed according to
the manufacturer’s instructions provided in the CellTiter 96
One Solution Proliferation Assay Kit (Promega). Brieﬂy, after
the incubation period, the cell monolayer was treated with
200 mL/well of MTS reagent solution (5:1 ratio in serum-
TABLE I. Starch-Conjugated Chitosan Microparticle Formulations used in the Enzymatic Degradation Study
Samplea GTM (mg/mL) Starch (%) Stirring Rate (rpm) Size (lm) EE (%)
ST-CHT 1a – 2 600 96.16 12.4 –
ST-CHT/G 1 15 2 600 116.6631.8 55.0162.65
Unloaded and gentamicin loaded microparticles were incubated in the presence of a-amylase at physiological concentrations up to 8 weeks.
The in vitro release of gentamicin was also evaluated in this enzymatic environment.
ST-CHT: starch-conjugated chitosan microparticles.
ST-CHT/G: gentamicin loaded starch-conjugated chitosan microparticles.
a Microparticles obtained using standard experimental conditions as described in the Materials and Methods section and elsewhere.11
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free DMEM culture medium without phenol red) and incu-
bated for further 3 h at 37C and in a humidiﬁed environ-
ment containing 5% of CO2; 100 mL of each well were then
ﬁltered (0.45 mm pore size) to eliminate the possible pres-
ence of solid particles, and transferred to a new 96-well
plate. The absorbance was determined in a microplate
reader (EL 312e Biokinetics, BioTek Instruments) at
490 nm. The results are expressed as the percentage of cell
viability in comparison with the negative control (i.e., for
each cell type, cells cultured in DMEM complete medium in
the absence of microparticles) for which 100% viability was
attributed. Latex rubber extract was used as positive control
(cytotoxic effect).8 The samples were tested in triplicates in
three independent assays.
A further aim of our study was to evaluate the inﬂuence
of several variations on the experimental conditions used to
produce different types of ST-CHT microparticles regarding
the particles’ biocompatibility. Thus, three modiﬁcations
were introduced to the standard procedure previously
described to produce the particles11: (i) two different cross-
linking agents, sodium tripolyphosphate (TPP), and glutaral-
dehyde (GA), at different concentrations (0.5, 1, and 2%)
were employed. Crosslinking was achieved by immersing
the obtained samples for 3 h into the crosslinker agent solu-
tion, (ii) the amount of starch in the composition of the ST-
CHT conjugate polymer solution used for the microparticles
preparation was varied (1, 2, and 4%), iii) the stirring rate
employed to form the emulsion was increased from 400 to
1000 rpm aiming at producing smaller sizes microparticles.
By means of the above mentioned modiﬁcations, 12 new ST-
CHT microparticles formulations were obtained at this
point. Table II shows the experimental conditions used to
produce the new different types of ST-CHT microparticles to
test them in the cytotoxicity screening. In addition, different
particle concentrations were also tested. Moreover, the
cytotoxicity resulting from the contact of the material
extracts over the cells was compared to the direct contact
particles-cell monolayer.
To obtain the ST-CHT microparticles extracts, the par-
ticles (formulation ST-CHT 1, Table II) were incubated in
complete cell culture medium for 24, 48, and 72 h at 37C
under constant shaking (100 rpm). This incubation was per-
formed using 0.5 mg microparticles per mL of complete cul-
ture medium. Subsequently to the incubation period, the
extraction medium containing potential toxic leachable and
degradation products was ﬁltered (0.45 mm pore size) and
added to the 80% conﬂuence cell layer. The cells were incu-
bated for further 72 h with this medium at 37C and in a
humidiﬁed environment containing 5% of CO2. The MTS
assay was performed for all microparticles tested, as well as
the particle extracts, as described above.
For all these cytotoxicity screening processes, the human
osteoblast cell line SaOs-2 was selected as cell type. In addi-
tion to the cytotoxicity screening using the unloaded micro-
particles, GTM-loaded particles were also tested
(formulation ST-CHT/G 1, Table I). Thus, SaOs-2 and L929
cell lines and AMSCs were used. Fluorescence microscopy
pictures (Biorevo BZ9000, Keyence, Japan) were taken 24
and 72 h after culture of the GTM-loaded particles with the
cells. Calcein-AM and propidium iodide was used for a live/
death staining.
Statistical analysis
All obtained values are reported as mean6 standard devia-
tion. The statistical analysis was performed with OriginPro
8.0 (Microcal1 software; OriginLab Corp). Normal distribu-
tion of the data was analyzed by Shapiro-Wilk test. Differen-
ces between samples were determined using Student’s t test
for two independent samples. p values< 0.05 were consid-
ered signiﬁcant.
TABLE II. Starch-Conjugated Chitosan Microparticles used for the Biocompatibility Evaluation
Sample GA (%) TPP (%) Starch (%) Stirring Rate (rpm) Size (lm) Cell Viability (% Control)
ST-CHT 1a – – 2 600 96.1612.4 77.1266.2
ST-CHT 2 – – 1 600 87.7629.1 71.1869.1
ST-CHT 3 – – 4 600 91.369.8 91.2461.8
ST-CHT 4 0.5 – 2 600 79.666.3 73.2168.6
ST-CHT 5 1 – 2 600 75.3613.4 65.8365.9
ST-CHT 6 2 – 2 600 74.3611.7 55.8769.1
ST-CHT 7 – 0.5 2 600 82.969.5 79.8164.0
ST-CHT 8 – 1 2 600 70.4610.4 76.7867.2
ST-CHT 9 – 2 2 600 71.3624.8 78.8163.8
ST-CHT 10 – – 2 400 207.1611.6 74.7068.9
ST-CHT 11 – – 2 800 606 7.4 76.2766.6
ST-CHT 12 – – 2 1000 106 9.1 79.3062.4
Twelve different microparticles formulations were obtained by modifying the standard processing conditions. The effect of the modifications
on the resulted cytotoxicity is expressed as percentage of cell viability in comparison to control (100% viability)
Common experimental conditions for all experiments:
Volume of polymer solution: 10 mL.
Mineral Oil 70 mL [1% Tween 80, (v/v)].
GA: glutaraldehyde; ST-CHT: starch-conjugated chitosan microparticles; TPP: sodium tripolyphosphate
Percentages of viable cell compared to negative control (100%-DMEM culture medium) as a result of the direct contact with starch-conjugated
chitosan microparticles
a Standard processing conditions as described in the Materials and Methods section and elsewhere.11
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RESULTS
Enzymatic degradation
Physicochemical characterization: Water uptake and
weight loss. As a result of immersion in aqueous solution,
hydrophilic materials undergo a process of swelling with
posterior uptake of large amounts of ﬂuid. Figure 1(A)
shows the water uptake percentage of the ST-CHT micropar-
ticles over a period of 60 days of incubation. In comparison
to PBS, signiﬁcantly higher values of water uptake
(160.165.6)% were obtained after incubation of the par-
ticles in a-amylase solution (p5 0.004). a-amylase was
used at a physiological concentration throughout the study.
The weight loss of ST-CHT microparticles is represented
graphically in Figure 1(B). Higher weight loss, that is, a
higher degradation rate, was obtained for the microparticles
incubated in the presence of a-amylase in comparison to
plain PBS (p5 0.00003). In fact, after 60 days of immersion
in the a-amylase solution, the ST-CHT microparticles were
extensively degraded, characterized by 67% of weight loss.
In contrast, when the particles were incubated in plain PBS
only 3% of weight loss was recorded. An association
between the weight loss and the extent of the particles’ deg-
radation can be concluded from the inserted SEM micro-
graph in Figure 1(B). The micrographs clearly demonstrate
the loss of the material integrity concomitant with the
weight loss.
Determination of reducing sugars in the supernatants. It
is well-known that enzymatic hydrolysis of polysaccharides
is accompanied by the release of glucose and several other
soluble sugar molecules to the degradation media.1 Figure
1(B) (bars) shows the concentration of reducing sugars
released into the solution after incubation of the ST-CHT
microparticles with a-amylase. Reducing sugars were found
in the supernatants where the microparticles were incu-
bated in the presence of the enzyme, but not in the control
supernatants (PBS only). As expected, prolongation of the
incubation time led to signiﬁcantly increasing amounts of
reducing sugars (p5 0.0002). In fact, after 60 days of degra-
dation, the concentration of reducing sugars quantiﬁed was
(18.0260.86) mg/mL.
Morphological evaluation of the degradation process:
SEM. The SEM micrographs presented in Figure 2 show the
morphology of ST-CHT microparticles before and after incu-
bation with PBS and with the enzymatic degradation solu-
tion. In the presence of the enzyme, the microparticles’ size
decreased and fractures and pores appeared at the surface
[Figure 2(E–H)]. In addition, the particles lost their spheri-
cal shape, indicating the progression of the degradation of
the particles when placed in contact with a-amylase in con-
trast to PBS [Figure 2(C,D)].
Chemical evaluation of the degradation process: FTIR-
Nuclear magnetic resonance (1H-NMR). Figure 3(A) shows
the FTIR spectra obtained for ST-CHT microparticles before
and after 60 days of a-amylase degradation. Relevant bands
assigned to polysaccharides as well as chitosan and starch
can be clearly identiﬁed. In the range of 900–1200 cm21,
the carbohydrate ﬁngerprint region, the three major starch-
speciﬁc bands 1030, 1080, and 1150 cm21 for the CAOAC
stretching can be clearly identiﬁed (triplet, broad band).
After the enzymatic hydrolysis, a clear decrease in the inten-
sity of those bands can be observed, indicating the action of
a-amylase in cleaving the CAOAC glycosidic linkages of
starch. On the contrary, when ST-CHT microparticles were
incubated in PBS only, no gross changes in chemical compo-
sition were observed.
Figure 3(B) shows the 1H-NMR spectrum of ST-CHT
microparticles before and after a-amylase degradation. The
spectrum of chitosan raw material is presented for compari-
son. After 60 days of a-amylase degradation, this peak at
5.5 ppm disappears [Figure 3(B)]. This peak corresponds to
the anomeric proton associated with a (1!4) linkages of
FIGURE 1. A: Water uptake profile of starch-conjugated chitosan
microparticles in PBS and PBS containing a-amylase (37 C, 100 rpm).
B: Degradation profiles (expressed as weight loss percentage) and
concentration of reducing sugars released from the microparticles
into the solution after incubation in PBS, and PBS containing a-
amylase (37 C, 100 rpm). Line graphs correspond to weight loss and
bar graphs represent the concentration of reducing sugars. The data
points in the figure represent the mean of three replicates (n5 3) and
the error bars the standard deviation. Insert SEM micrographs shows
the extent of the material degradation concomitant with the degrada-
tion profiles. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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the starch material. Thus, this is an indication of the action
of the enzyme cleaving the glycosidic linkages in the starch.
In addition, the multiplet signal at 4-ppm, assigned to the
internal protons of starch, also disappear after a-amylase
degradation. As a result, changes in the multiplet signal
shape can be observed, leading to the clariﬁcation of the
chitosan-characteristic peaks that were overlapped with the
starch multiplets in the same region of the spectrum.
FIGURE 2. SEM micrographs showing the morphology of surfaces and the shape of starch-conjugated chitosan microparticles. A,B: before deg-
radation. C,D: 60 days after incubation in plain PBS solution. E,F: 14 days after incubation in a-amylase solution. G,H: 60 days after incubation in
a-amylase solution.
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Effect of a-amylase degradation on the release kinetics
of gentamicin
Figure 4 shows the release proﬁles of GTM from ST-CHT
microparticles in PBS and in the presence of a-amylase.
Interestingly, the initial burst release (up to 12 h) of the
GTM was unaffected by the presence of the enzyme. How-
ever, from that point in time on, the GTM was released sig-
niﬁcantly faster when a-amylase was present (p50.028).
This effect became more pronounced from the second day
on, where 71% GTM was released from the ST-CHT micro-
particles in the presence of the enzyme, whereas only 59%
was released from the sample incubated in PBS only.
Cytotoxicity evaluation
The biocompatibility of the ST-CHT microparticles was eval-
uated by means of a cytotoxicity screening using several cell
types. Both unloaded and GTM-loaded microparticles were
evaluated. The microparticles were found to be highly bio-
compatible with SaOs-2 (osteoblasts) and L929 (ﬁbroblasts)
cells [Figure 5(A)]; 77.12% cell viability was obtained as a
result of incubating the unloaded particles with osteoblast
cells SaOs-2 for 72 h. Similar cell viability values, that is,
70.01%, were obtained for the GTM-loaded microparticles.
In fact, no signiﬁcant difference was observed on the bio-
compatibility of unloaded and GTM-loaded microparticles
over SaOs-2. The cells appeared microscopically healthy and
no visual differences could be observed when comparing
with the control cells (cultured without microparticles). For
the L929 cell line, 83.08% viability was obtained for the
unloaded particles whereas 89.72% viability was obtained
for the GTM-loaded particles after 72 h incubation. The par-
ticles added to the ﬁbroblast culture did not result into any
detrimental effect. No signiﬁcant differences were obtained
for the cell viability values when comparing them to the
negative control (p50.064). However, cell viability values
higher than 76% were obtained as a result of incubating
the microparticles for 72 h with AMSCs. No signiﬁcant dif-
ference was observed on the biocompatibility of unloaded
and GTM-loaded microparticles over AMSCs. The calcein-
AM/propidium iodide results [Figure 5(B–G)] are in accord-
ance with the MTS ﬁndings. All cells appear to be viable
(green ﬂuoresce indicating viable cells) while very few cells
seem to be nonviable (red ﬂuoresce indicating apoptotic
cells).
Effect of material extracts. A further cytotoxicity evaluation
was conducted using extracts of the ST-CHT microparticles
over SaOs-2 cells. Figure 6(A) shows that the extraction
time does not signiﬁcantly inﬂuence cell viability (p50.2).
Cell viability values were found to be above 70%, when
compared with negative control (100%).
FIGURE 3. A: FTIR spectra of starch-conjugated chitosan microparticles before (gray) and after (black) enzymatic degradation with a-amylase for
60 days. The diminution in the intensity of the bands, as result of the action of a-amylase cleaving the CAOAC glycosidic linkages of starch, is
indicated with an arrow. B: 1H-NMR spectra of the microparticles before (gray) and after (black) 60 days of degradation in presence of a-
amylase. The spectrum of chitosan raw material used to produce the microparticles is presented for comparison (discontinuous line). Symbols
indicating peaks or group of peaks: #: starch (a (1!4) glycosidic linkages, singlet), •: chitosan (deacetylated unit, doublet), —: area- starch (inter-
nal protons, multiplets). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 4. Release profiles of gentamicin from starch-conjugated chi-
tosan microparticles in PBS (0.01M, pH5 7.4) (--) and PBS contain-
ing 150.0 U/L a-amylase (-x-) solutions.
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Effect of the crosslinking agent and its
concentration. Two different crosslinking agents, that is, GA
and TPP at three different concentrations were used to pro-
vide structural stability to the microparticles. Table II sum-
marizes the percentage of cell viability depending on the
concentration and on the crosslinking agent used. Signiﬁ-
cantly higher cytotoxicity (55.87% cell viability) was
obtained for GA when compared with TPP (p50.002) and
to the negative control (100%; p50.0002). This toxic effect
was found to be concentration-dependent. A considerable
improvement in cell viability (i.e., over 70%) was observed
when decreasing the GA concentration from 2 to 0.5%
[Table II and Figure 6(B)]. However, values higher than 75%
were obtained for cell viability when TPP is used as a cross-
linking agent. Those resulted independently of the concen-
tration used. In fact, the cell viability results are in the same
range as the ones obtained when no crosslinking agent was
used (p50.66).11
Effect of the amount of starch in the composition of the
ST-CHT microparticles. An enhancement of cell viability
was obtained by increasing the amount of starch in the
composition of the ST-CHT microparticles [Figure 6(C)]. Cell
viability values increased from 71 to 91% when the concen-
tration of starch was raised from 1 to 4% (Table II).
Effect of the ST-CHT microparticles’ concentration. A
range from 0.25 to 5 mg particles per mL cell culture
medium was selected to test the effect of the microparticles’
concentration. Cell viability values >70% were obtained for
each concentration [Figure 6(D)]. No signiﬁcant differences
FIGURE 5. Biocompatibility screening of the starch-conjugated chitosan microparticles by means of MTS assay. A: Optical density of the MTS
solutions after culture of SaOs2, L929, and AMSCs in the presence of unloaded and gentamicin-loaded starch-conjugated chitosan microparticles
for 72 h (microparticles ST-CHT 1 and ST-CHT/G 1 from Table I were used). Calcein-AM and propidium iodide (live/death staining) pictures of
SaOs-2, L929, and AMSCs after culture in the presence of gentamicin-loaded starch-conjugated chitosan microparticles for: (B–D) 24 h and (E–G)
72 h. The scale bars represent 400 mm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
8 BALMAYOR ET AL. BIODEGRADATION AND BIOCOMPATIBILITY OF GTM DELIVERY FORMULATION
resulted from the comparison among the different micropar-
ticles’ concentrations tested.
Effect of the ST-CHT microparticles’ size. By increasing the
stirring speed from 400 to 1000 rpm during the micropar-
ticles’ production, particles with sizes from 207.16 11.6 to
1069.1 mm were obtained. Decreasing the microparticles’
size did not induce a signiﬁcant difference in cell viability
[Figure 6(E)]. Values of cell viability higher than 74% were
obtained for all four differently sized particles tested. No
signiﬁcant differences were obtained when the particles
were compared among them. Figure 6(F–H) shows the
results of the calcein-AM/propidium iodide staining for
SaOs-2, L929, and AMSCs cultured in direct contact with the
smallest ST-CHT microparticles obtained in our study (size
1069.1 mm). The cells appear to be highly viable as indi-
cated by the markedly green ﬂuorescence patterns. No cell
death was observed.
DISCUSSION
A biomaterial designed for biomedical applications will
interact with human tissues and ﬂuids after implantation,
which might initiate their degradation process. Chemical
and enzymatic oxidations, nonenzymatic hydrolysis
FIGURE 6. Biocompatibility screening of the starch-conjugated chitosan microparticles produced by variations on the processing parameters.
Optical density of the MTS solutions after culture of SaOs2 for 72 h in the presence of: A: microparticles extracts obtained in culture medium for
24, 48, and 72 h (microparticles ST-CHT 1 from Table II were used), B: microparticles obtained by the use of different concentrations of GA and
tripolyphosphate as crosslinking agents (microparticles ST-CHT 4–9 from Table II were used), C: microparticles obtained by the use of different
percentages of starch in their composition (microparticles ST-CHT 1–3 from Table II were used), D: different concentrations of microparticles in
the range of 0.25–5 mg/mL culture medium (microparticles ST-CHT 1 from Table II were used), E: microparticles with different sizes (micropar-
ticles ST-CHT 1, 10–12 from Table II were used). Calcein-AM and propidium iodide (live/death staining) pictures of the cells cultured in direct
contact with the starch-conjugated chitosan microparticles: (F) SaOs-2, (G) L929, and (H) AMSCs. The scale bars represent 200 mm. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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(catalyzed by acids, bases, or salts) and enzymatic hydroly-
sis caused by the action of enzymes are some of the routes
for degradation to occur.1 a-amylase is expected to partici-
pate in the degradation of starch-based biomaterials that
perform their function within the human body (i.e., in those
tissues were this enzyme occurs naturally). Here, we show
that the developed ST-CHT microparticles were susceptible
to degradation by physiological concentrations of a-amylase.
The material underwent ﬁrst a swelling process as indicated
by the high amounts of water uptake upon incubation in
the aqueous solution. This fact was expected since both
materials, chitosan and starch are polysaccharides. Thus,
they provide hydrophilic characteristics to the resulting
microparticulated system. It could also be associated to the
presence of a-amylase in the solution. Azevedo et al.
reported that the partial degradation of the material result-
ing from enzymatic hydrolysis led to enhanced permeabil-
ity26 and thus increased values of water absorption over
time. The action of the enzyme a-amylase on the degrada-
tion of the microparticles was clearly demonstrated. The
material lost 67% of its weight after 60 days of incubation.
Moreover, clear morphological changes could be detected.
SEM microscopical observations revealed a complete loss of
material integrity. Additionally, structural changes occur as
result of the enzymatic action. This was evidenced by spec-
troscopic techniques such as FTIR and NMR. FTIR demon-
strated the action of the a-amylase in cleaving the CAOAC
glycosidic linkages of starch. Several authors have reported
that any loss in starch content will result in a decrease in
the absorbance in the carbohydrate ﬁngerprint region (900–
1200 cm21).27,28 However, proton NMR showed the disap-
pearance of several characteristic starch peaks after enzy-
matic action. A very pronounced effect was found on the a
(1!4) glycosidic linkages of the starch. This was an
expected result, since a-amylase is known to have a speciﬁc
action on the mentioned starch bonds. This leads to the
release of degradation products to the surrounding media,
which could be measured. In the case of starch, glucose,
and several other sugar molecules are expected to be
released.1,26 In fact, increasing amounts of reducing sugars
were found in the supernatants of ST-CHT microparticles.
The absence of speciﬁc a (1!4) glycosidic linkages in chi-
tosan leads to the assumption that the amount of quantiﬁed
sugars corresponds to the degradation of the starch mate-
rial in the blend.
The impact of the enzymatic degradation over the
release of GTM was observed 24 h after the immersion of
the particles in the degradation media. The initial burst
release (ﬁrst 12 h) was not signiﬁcantly changed. This
result was to be expected if we consider that the initial
burst release is attributable to the release of the drug that
is present at the outermost layer of the microparticles and
is thus quickly released before the enzymatic degradation
starts to take place. Indeed, we have observed <5% weight
loss after 12 h of microparticles’ incubation. In our previous
study, we have reported that about 54% of the entrapped
drug was released from this material during the ﬁrst
24 h.11 When studying the drug release mechanism, a
non-ﬁckian diffusion was obtained for this microparticular
system in PBS, thus indicating a contribution of polymer
relaxation and drug diffusion factors to the GTM release.
Here, the obtained results in the presence of the enzyme
during the ﬁrst 24 h are in accordance with the previous
published data. At that time, the material has lost 15% of
its initial weight and the porosity starts to be formed allow-
ing the GTM to be easily released to the surrounding media.
In fact, over 65% of the GTM was released 24 h after incu-
bation of the microparticles, demonstrating the impact of
the matrix biodegradation on the release of the entrapped
drug. It can be concluded that after the initial burst release,
a diffusion phenomenon is responsible for the release of the
drug until enzymatic degradation starts to take place and
ﬁnally controls the release mechanism.
Biodegradation is often desired when designing biomate-
rials for tissue engineering. This is especially true in drug
delivery applications, were the main aim will be to the con-
trol of the delivery rate. However, there is major concern
associated with the toxic effect of resulting degradation
products and leachable molecules. Both unloaded and GTM-
loaded ST-CHT particles developed here resulted biocompat-
ible with the three cell types tested. A toxic effect was
obtained, however, when GA was used during the particles’
fabrication. This result is in accordance with previously
published data on the toxicity of this crosslinking agent.29 It
is worth mentioning that this toxic effect was clearly
concentration-dependent. Zhong et al. reported the use of
vapors of GA to efﬁciently crosslink polysaccharide struc-
tures without toxic effect associated.30 The use of TTP is
also an alternative. As reported here, no toxic effect was
observed even at high concentrations. However, the pres-
ence of starch clearly enhanced the biocompatibility of the
ST-CHT blend. This polysaccharide has been reported as
highly biocompatible. Its use as part of blended materials or
composites will highly improve the biocompatibility of the
resulting biomaterial.
CONCLUSION
The combination of chitosan and oxidized starch resulted in
very hydrophilic and biodegradable microparticles. High val-
ues of water uptake (160%) and weight loss (67%) were
found 60 days after enzymatic degradation in vitro. Addi-
tionally, increasing amounts of soluble sugars were released
to the media. They resulted to be nontoxic when an extract
of the particles (i.e., containing degradation products and
leachable molecules) was added to cells in culture. Cell via-
bility studies indicated that the ST-CHT microparticles had a
negligible effect over SaOs-2 and L929 cell lines as well as
AMSCs. Moreover, increasing amounts of starch in the blend
composition resulted in increased cell proliferation. How-
ever, some toxicity was indeed observed for the micropar-
ticles produced using GA. A highly porous microparticular
matrix was obtained after degradation. As a consequence,
the matrix permeability also increased leading to increased
water penetration. Thus, diffusion of the entrapped gentami-
cin was favored. The initial stage of drug release is then
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controlled by diffusion. At a certain point, when the degra-
dation process is taking place, the remaining amount of
entrapped drug is released accordingly. Ultimately, the deg-
radation rate of the material will control the release kinetics
of the encapsulated drug.
The results obtained in this study allow us to corrobo-
rate starch as a biocompatible and biodegradable polysac-
charide that can be used to enhance such features in its
blended materials. We have been able to successfully conju-
gate chitosan with starch. Thereby, a highly biocompatible
and biodegradable system was produced. This system could
serve as a biomatrix not only for drug delivery, but also for
many other tissue engineering and biomedical applications.
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